Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKesson
Daiichi Sankyo
Chinese Patent Office
Teva
Chubb
Fish and Richardson
Farmers Insurance
Johnson and Johnson
AstraZeneca

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,458,811

« Back to Dashboard

Which drugs does patent 6,458,811 protect, and when does it expire?


Patent 6,458,811 protects EVISTA and is included in one NDA.

This patent has forty-three patent family members in thirty-three countries.

Summary for Patent: 6,458,811

Title: Benzothiophenes formulations containing same and methods
Abstract:This invention provides compounds of formula I ##STR1## and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
Inventor(s): Arbuthnot; Gordon Nelson (Indianapolis, IN), Dalder; Brian Weston (West Lafayette, IN), Hartauer; Kerry John (Indianapolis, IN), Luke; Wayne Douglas (West Lafayette, IN), Stratford, Jr.; Robert Eugene (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/812,896
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997ABRXYesYes► Subscribe► SubscribeYY USE FOR PREVENTION OF BREAST CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,458,811

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,719 Benzothiophenes, formulations containing same, and methods► Subscribe
8,030,330Benzothiophenes, formulations containing same, and methods► Subscribe
6,894,064 Benzothiophenes, formulations containing same, and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,458,811

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina006387► Subscribe
Austria464897► Subscribe
Australia2215497► Subscribe
Australia723797► Subscribe
Brazil9708248► Subscribe
Canada2250191► Subscribe
China1162153► Subscribe
China1213967► Subscribe
Colombia4780022► Subscribe
Czech Republic300341► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Colorcon
Merck
Cerilliant
Fish and Richardson
Cantor Fitzgerald
Deloitte
Daiichi Sankyo
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot